Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

Published:2024-06-16 Issue:2 Volume:166 Page:905-906
ISSN:0020-7292
Container-title:International Journal of Gynecology & Obstetrics
language:en
Short-container-title:Intl J Gynecology & Obste

Author:

Douxfils Jonathan¹²³^ORCID,Beaudart Charlotte⁴⁵^ORCID,Dogné Jean‐Michel¹^ORCID

Affiliation:

1. Department of Pharmacy, Research Unit in Clinical Pharmacology and Toxicology, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine University of Namur Namur Belgium

2. QUALIblood sa Namur Belgium

3. Department of Biological Hematology CHU Clermont‐Ferrand, Hôpital Estaing Clermont‐Ferrand France

4. Department of Biomedical Sciences, Research Unit in Clinical Pharmacology and Toxicology, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine University of Namur Namur Belgium

5. WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging Division of Public Health, Epidemiology and Health Economics University of Liège Liège Belgium

Publisher

Wiley

Link

https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1002/ijgo.15740

Reference4 articles.

1. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

2. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant

3. Food and Drug Administration.2023. Accessed July 6 2023.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216578Orig1s000MedR.pdf

4. European Medicines Agency.2023. Accessed 29 January 2024.https://www.ema.europa.eu/en/documents/product‐information/veoza‐epar‐product‐information_en.pdf.